Visionix complements Revenio's vision – clear strategy, valuable framework

Translation: Original published in Finnish on 4/14/2026 at 8:22 am EEST.

Revenio announced on Monday that it is acquiring the French Visionix group for a debt-free purchase price of 290 MEUR. In our view, the acquisition is strategically excellent and addresses the biggest gap in the company's product portfolio by giving Revenio immediate access to the fast-growing OCT market (Optovue). The transaction will practically double Revenio's revenue, but at the same time, it will significantly decrease the company's relative profitability in the short term. In addition, based on 2025 realized earnings, Visionix's valuation in the acquisition is high (EV/EBITDA ~18x), and financing the transaction requires a directed share issue to the sellers, a rights issue, and significant debt financing. We believe that this strategically justified acquisition, once significant synergies are realized, will create shareholder value, but there are still many uncertainties. Our estimates will change significantly once the deal is completed, and we will update them in full as the details of the transaction become clearer. At that point, we will also revisit our view on the investment case.

Visionix brings the missing pieces to Revenio's portfolio

We have repeatedly highlighted in our previous analyses that optical coherence tomography (OCT) is the biggest and most strategically critical gap in Revenio's product offering. With the Visionix acquisition, this gap is eliminated as Revenio gains a portfolio of established OCT and OCT-A devices. We believe OCT is becoming the standard of care in both ophthalmology and optometry, with a market potential of approximately 0.7 BUSD. Visionix's revenue breakdown is not yet known, but the company's CEO stated that OCT revenue is around 30 MEUR.

Based on this, Visionix/Optovue would have a 4-5% market share in a segment that we believe is dominated by Zeiss, Topcon, and Heidelberg. However, we believe the lead of the aforementioned companies has narrowed in OCT angiography (OCT-A), which is an extension of OCT technology. OCT-A enables imaging of the retinal and choroidal vasculature without injecting a contrast agent into the patient, which is a key difference from traditional fluorescein angiography (FA). Optovue has been on our radar as a potential acquisition target for Revenio before.

In addition to OCT, Visionix's product portfolio consists of multimodal diagnostic platforms, wavefront-based refraction systems, fundus imaging devices, telehealth and connectivity capabilities, and lens finishing solutions under the well-known Visionix, Optovue, Briot, and Weco brands, among others. Visionix's offering thus covers a significant portion of the patient care pathway, from visual assessment and structural imaging of the eye to lens processing and edging. In our view, the companies' product portfolios are highly complementary, with little overlap, and we see significant cross-selling opportunities, especially in the US and European markets. The combined company will also gain access to new negotiations due to its comprehensive offering.

Source: Revenio's Visionix acquisition investor presentation April 13, 2026.

According to the company's estimate, the arrangement expands Revenio's total addressable market (TAM) by roughly 2.5 times to a total of 2.5 BUSD. After the acquisition, Revenio's offering would cover most of the approximately 4 BUSD ophthalmic diagnostics market and enable comprehensive total solutions. In our view, this opens up a long and attractive growth path for the company if the strategy is successful. Strategically, we believe the acquisition is a logical continuation of Revenio's strategic shift from a device supplier to a total solutions provider, as Visionix brings strong expertise in diagnostic platforms, refraction, and lens finishing solutions.

The company's size will double, but margins require work

Visionix's revenue in 2025 was 143.4 MEUR, which was 1.1% less than in 2024 (145.1 MEUR). The company's adjusted EBITDA was 16.6 MEUR (11.5% margin), an increase of 11.4% from 14.9 MEUR in the previous year. According to the company's CEO, profitability has suffered since the COVID-19 pandemic due to strong cost inflation (especially components) and unfavorable exchange rate movements, among other factors. We understand that the company initiated a significant profitability improvement program last year, aiming for a 4-5% margin improvement. However, with current information, it is difficult to say how solid the potential profitability improvement is. Visionix's profitability is in any case clearly lower than Revenio's (2025 EBITDA margin 27.2%), which dilutes the combined group's margins.

 Revenio aims to improve its EBITDA by over 20 MEUR through synergies by the end of 2029. The company expects to achieve some 70% of this by the end of 2027, which we believe is mainly driven by cost synergies. In our view, the estimated synergy potential is credible, but the realization of sales-side synergies always involves significant uncertainty. However, Revenio has a very strong track record with the CenterVue integration, and we consider it likely that a significant portion of the synergies will be achieved on schedule. Interestingly, Visionix also has its own manufacturing operations, which Revenio has historically outsourced.

Revenio estimates that the integration process and the achievement of targeted synergies will require ~20 MEUR in non-recurring costs, of which about 30% will be capitalized on the balance sheet in connection with IT systems. The costs are mainly related to organizational restructuring, IT system integration, rebranding, marketing, and project management support. The company estimates that the majority of the non-recurring costs will be incurred during 2026 and 2027.

In connection with the transaction, Revenio also set ambitious financial targets for the new entity. The company targets an EBITDA margin of 25% in 2028-2029 and as high as 30% after 2030. Regarding growth, the goal is still to grow three times faster than the market, but the bar was raised slightly because Visionix's market segments are inherently growing faster than Revenio's older segments.

The deal's valuation is high – at least relative to current earnings

The enterprise value (EV) of the transaction is 290 MEUR, which is high compared to Visionix's historical results. Valuation multiples calculated based on 2025 pro forma figures are significantly higher than Revenio's (excluding the EV/S multiple due to the profitability difference), which is likely the main reason for yesterday's negative share price reaction. On the other hand, the valuation appears reasonable if we assume the CEO's statements about significant margin improvement are accurate and we increase the realized 2025 margin by 4 percentage points (marked as 2025+ in the table). If we also note that the planned synergies (70% of a total of 20 MEUR) are added to the already improved profitability, then the valuation would look very attractive by 2027 (marked as 2027++ in the table). We note that for the 2027 figures, we use the same revenue level as in 2025, even though the company is presumed to have grown significantly by then.

The closest thing to a fact right now is, of course, the high historical multiples, but in our view, the valuation paid is justifiable by a significant improvement in strategic position and likely high synergies. In our view, however, Revenio has had to give up a significant portion of the synergy benefits to finalize the transaction, which means that value creation requires successful integration. In the long term, we consider it likely that the acquisition will create shareholder value, but there is a lot of work ahead in the coming years.

Share issues also reduce the attractiveness of the acquisition

The purchase price to be paid to the sellers is 250 MEUR, of which 194.3 MEUR will be paid in cash and 55.7 MEUR in new Revenio shares (2.5 million shares at a price of 22.40 euros). It is worth noting that the price of the company's own shares is significantly higher than the current share price, which reduces shareholder dilution. At the same time, the sellers will become significant shareholders of Revenio (an ownership of ~8.5%). Of the cash consideration, 17.3 MEUR is deferred payment.

The financing arrangement is very large relative to Revenio's size:

• A 130 MEUR amortizing term loan.
• An 80 MEUR bridge financing, which is intended to be repaid with an 80 MEUR rights issue to be carried out in late 2026.
• The combined company's net debt/EBITDA ratio is high at 4.4x on a pro forma basis, but will decrease to a reasonable level of 2.5x after the rights issue.

We consider it a positive that Revenio received a loan with a low interest rate. The largest shareholder, William Demant Invest, and the sellers of Visionix have committed to subscribing to a share of the upcoming share issue corresponding to their ownership (a total of ~31%). The Board has committed to not proposing a dividend until the deferred purchase price has been paid, which means a pause in dividend payments. This does not come as a surprise, as the previous dividend proposal was conditional, which already hinted at a potential significant acquisition. Overall, financing is secured, and we estimate that the combined company will generate strong cash flow, with indebtedness at a reasonable level after the rights issue.

Conditions for value creation are in place, but there are also risks involved

Our initial reaction to the Visionix acquisition is mixed. We consider the strategic compatibility of the companies to be excellent and believe Revenio will significantly benefit from the expanding product portfolio and scale. We consider the expansion into the OCT area particularly important, where Visionix's offering is, in our view, at least competitive. Revenio's total market is expanding strongly, and with a broader offering, the company's competitive position improves, and resources, for example, for product development, are further strengthened. We are also confident that significant synergy benefits will arise, even though they require effort, costs, and time. We believe all the prerequisites for an acquisition that creates significant shareholder value are in place, and Revenio has an excellent track record with the CenterVue acquisition in Italy.

On the other hand, the price to be paid for Visionix is high, at least compared to historical data, and creating shareholder value requires successful integration and at least partial achievement of synergy benefits. Paying multiples higher than one's own valuation multiples is painful, even if it can be well-justified in this case. For the time being, we do not have a clear picture of Visionix's products' competitiveness, sustainable profitability, or cash flow generation capabilities. In addition, integrations always involve risks (such as hidden cultural differences), even if the companies appear to be a very good fit on paper. These uncertainties, combined with the tendency of large acquisitions to fail, mean that we do not believe the acquisition can be considered a guaranteed success. Risks are increased by significant debt financing and dilution of the share capital at a relatively low valuation level.

Partially, the perspective also depends on the time horizon. In the long term, we are confident about the relatively positive development and value creation of the acquisition, and we believe the strategic move was partly a necessity. In the short term, however, there is significant uncertainty and a potentially heavy integration process ahead, which could easily divert attention from the "old" business. In the short term, threats are easily emphasized, while opportunities require time.

The arrangement will significantly alter Revenio's investment profile, and our forecasts for both earnings and balance sheet structure will change completely once the acquisition is completed. We consider the acquisition almost certain to close, but visibility into short-term developments is poor in this exceptional situation. Revenio withdrew its previous guidance for 2026, and several other factors important for forecasts (Visionix's revenue distribution across different products, estimated profitability levels in the coming years, depreciation levels, and reporting) remained unclear for now. Revenio will issue new guidance once the transaction has been completed, estimated to be by the end of Q2'26. For several other questions, we await further information from the upcoming Capital Markets Day, where the overall picture will finally become clearer. We will update our view on Revenio once we have had a closer look at Visionix and have a better understanding of the overall picture.